Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for diltiazem
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on diltiazem or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on diltiazem and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. Accelerated coronary artery disease is a major cause of late morbidity and mortality among heart-transplant recipients. Because calcium-channel blockers can suppress diet-induced atherosclerosis in laboratory animals, we assessed the efficacy of diltiazem in preventing coronary artery disease in transplanted hearts.Consecutive eligible cardiac-transplant recipients were randomly (...) assigned to receive diltiazem (n = 52) or no calcium-channel blocker (n = 54). Coronary angiograms obtained early after cardiac transplantation and annually thereafter were used for the visual assessment of the extent of coronary artery disease. The average diameters of identical coronary artery segments were measured on the angiograms obtained at base line and at the first and second follow-up examinations.In the 57 patients who had all three angiograms, the average coronary artery diameter (+/- SD
Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. 2159250 1990 06 01 2013 11 21 0003-4819 112 9 1990 May 01 Annals of internal medicine Ann. Intern. Med. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. 707-8 Bakris G L GL Ochsner Clinic, New Orleans, Louisiana. eng Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States Ann Intern Med 0372351 0003-4819 0 (...) Angiotensin-Converting Enzyme Inhibitors 69PN84IO1A Enalapril E7199S1YWR Lisinopril EE92BBP03H Diltiazem AIM IM Ann Intern Med. 1991 Jan 15;114(2):167-8 1984399 Angiotensin-Converting Enzyme Inhibitors therapeutic use Clinical Trials as Topic Diabetes Complications Diltiazem adverse effects therapeutic use Enalapril adverse effects analogs & derivatives therapeutic use Female Humans Lisinopril Male Middle Aged Prospective Studies Proteinuria drug therapy etiology 1990 5 1 1990 5 1 0 1 1990 5 1 0 0
An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. This multicenter, factorial-design trial assessed the safety and additive antihypertensive efficacy of a slow-release (SR) formulation of diltiazem hydrochloride given alone or in combination with hydrochlorothiazide for treatment of mild to moderate hypertension. After a 4- to 6-week placebo run-in period, 297 qualifying patients were (...) randomized to receive placebo, 1 of 4 doses of diltiazem SR monotherapy, 1 of 3 doses of hydrochlorothiazide monotherapy, or 1 of 12 possible combinations of diltiazem SR and hydrochlorothiazide for 6 weeks. A dose-related reduction in blood pressure was demonstrated for each drug as monotherapy and for the two drugs in combination. Absolute blood pressures of patients who received combination therapy were lower by an overall mean of 3.0 mm Hg diastolic and 8.0 mm Hg systolic vs diltiazem SR used alone
The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. We studied the effect of diltiazem on mortality and reinfarction in 2466 patients with previous infarction from 38 hospitals in the United States and Canada. The patients were randomly assigned to receive diltiazem (240 mg per day, n = 1234) or placebo (n = 1232) and followed for 12 to 52 months (mean, 25). Total mortality rates were nearly identical (...) among the two treatment groups (167 and 166, respectively), as were cumulative mortality rates. There were 11 percent fewer first recurrent cardiac events (death from cardiac causes or nonfatal reinfarction) in the diltiazem group than in the placebo group (202 vs. 226; Cox hazard ratio, 0.90; 95 percent confidence limits, 0.74 and 1.08). A significant (P = 0.0042) bidirectional interaction between diltiazem and pulmonary congestion was observed on x-ray examination. In 1909 patients without
Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. We performed a multicenter, double-blind, randomized study to evaluate the effect of diltiazem on reinfarction after a non-Q-wave myocardial infarction. Nine centers enrolled 576 patients: 287 received diltiazem (90 mg every six hours) and 289 received placebo. Treatment was initiated 24 to 72 hours after the onset of infarction and continued for up to 14 days (...) . The primary end point, reinfarction, was defined as an abnormal reelevation of MB creatine kinase in plasma within 14 days. Reinfarction occurred in 27 patients in the placebo group (9.3 percent) and in 15 in the diltiazem group (5.2 percent)--a 51.2 percent reduction in cumulative life-table incidence (P = 0.0297; 90 percent confidence interval, 7 to 67 percent). Diltiazem reduced the frequency of refractory postinfarction angina (a secondary end point) by 49.7 percent (P = 0.0345; 90 percent confidence